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ABSTRACT
Antibiotic-associated diarrhoea (AAD) is a common cause of morbidity and mortality. Older individuals in 
long-term care facilities are particularly vulnerable due to multisystem illnesses and the prevailing condi-
tions for nosocomial infections. Lactoferrin, an antimicrobial protein in human breastmilk, was tested to 
determine whether it would prevent or reduce AAD, including Clostridium difficile in tube-fed long-term care 
patients. Thirty patients were enrolled in a randomized double-blind study, testing eight weeks of human re-
combinant lactoferrin compared to placebo for the prevention of antibiotic-associated diarrhoea in long-term 
care patients. Fewer patients in the lactoferrin group experienced diarrhoea compared to controls (p=0.023). 
Based on the findings, it is concluded that human lactoferrin may reduce post-antibiotic diarrhoea.
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INTRODUCTION
Up to 25% of patients treated with broad-spectrum 
antibiotics experience diarrhoea (1), and this anti-
biotic-associated diarrhoea (AAD) can vary from 
mild nuisance loose or watery stools to severe diar-
rhoea, including colitis. Patients in long-term care 
are particularly vulnerable, and AAD is an impor-
tant cause of disability and death in this popula-
tion (2). However, Clostridium difficile, a known 
aetiologic agent, explains less than half of these 
cases. The consequences of AAD can be severe, 
leading to debility due to volume depletion, enteral 
protein loss, and a chronic inflammatory state (3). 
Ironically, AAD is also being treated with antibio-
tics and may contribute to the growing problem of 
antibiotic-resistant pathogens (4). To prevent post-
antibiotic diarrhoea, we employed a normal hu-
man breastmilk protein—lactoferrin—which has 
both anti-inflammatory and antimicrobial prop-
erties (5) and has recently been shown to reduce 
the duration of diarrhoea in children (6). We tested 
whether recombinant human lactoferrin grown 
in rice could prevent post-antibiotic diarrhoea in 
long-term care residents.
MATERIALS AND METHODS
Nursing-home residents were randomized to re-
ceive, by gastrostomy tube, lactoferrin (5 mg/mL) 
or placebo via a flush solution. Both product and 
placebo were dissolved in 600 mL of 0.3% saline 
solution and were similar in appearance, ensuring 
that patients and staff be blind to treatment condi-
tion. The solution was administered each day for 56 
days. Nurses and nursing assistants recorded stool 
quality on each shift, and stool samples were tested 
for C. difficile at enrollment, day 14, 42, and 56.  
We conducted an interim analysis when 50% of 
the  enrollment  goal  was  completed  (16  partici-
pants), leading to a change in the inclusion criteria 
and the randomization scheme. Thus, the study 
was divided into two phases—phase 1 and phase 
2. During phase 1, patients initially colonized with 
C. difficile (C. difficile antigen present in stool sam-
ples) were excluded from participation, leading to 
38% (6/16) of the participants being disenrolled 
immediately. Phase 2 amended the protocol such 
that the participants be only excluded if they had 
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(stool samples testing positive for C. difficile anti-
gen and toxin A and B). Since all participants 
who were excluded from the study due to C. difficile 
colonization were from the lactoferrin group (6/6), 
we altered the randomization scheme in phase 2. 
Phase 2 randomization was changed to two lacto-
ferrin enrollees for each placebo enrollee to ensure 
a large sample-size enough for comparison between 
lactoferrin and control groups.
Study subjects
Patients at the 41-bed ventilator rehabilitation unit 
of the Johns Hopkins Geriatric Center beginning 
a new course of broad-spectrum antibiotics (not 
including metronidazole, vancomycin, and lin-
ezolid) were approached for participation in this 
study, if they had met the following inclusion cri-
teria: (a) nutrition via an enteral feeding-tube; (b) 
free from antibiotics for 10 days before entry into 
the study; (c) not allergic to rice or rice products; 
and (d) not colonized with C.  difficile (phase  1) or 
no signs or symptoms of clinically-confirmed C. 
difficile-assoc-iated disease (phase 2).
C. difficle testing
All stool samples were tested for C. difficile anti-
gens using a rapid enzyme immunoassay Techlab 
(CDIFF-CHEK). Samples testing positive for C. dif-
ficile antigens were further tested for cytotoxins 
using a cell culture cytotoxicity assay (7). Samples 
testing positive for C. difficile antigen and toxin A 
and B were classified as infected with C. difficile. 
Samples that tested positive for C. difficile antigen 
only were classified as colonization. 
Statistical analysis
Diarrhoea was defined as two or more loose stools 
(conforming to the shape of a container) within a 
24-hour period. Each 24-hour period meeting this 
criterion was classified as a diarrhoea-day. Compari-
sons between lactoferrin and control groups were 
made on the mean and the total number of diar-
rhoea-days. Further, an episode of diarrhoea was 
defined as consecutive days of diarrhoea, ending 
after two successive 24-hour periods without di-
arrhoea. The participants were also compared on 
time-to-first episode of diarrhoea, or time from en-
rollment into the study to the first diarrhoea-day. 
The participants never experiencing diarrhoea were 
censored at the last day of participation in the study 
as diarrhoea-free.   
Non-parametric tests were used for comparisons 
between lactoferrin and control groups because of 
the small sample-sizes and failure to meet normali-
ty assumptions for continuous data. Categorical 
variables were compared using Fisher’s exact test, 
and statistical significance was assessed using the 
Wilcoxon signed-rank test for continuous parame-
ters. The group differences in time-to-diarrhoea 
were assessed using the log-rank test.     
Ethical aspects
Informed consent was obtained from the patient 
or healthcare agent before enrollment. The Institu-
tional Review Board of the Johns Hopkins Medi-
cine approved the study. 
RESULTS
Data relating to stool for 22 participants (13 con-
trol and 9 lactoferrin participants) were analyzed. 
The remaining eight participants were excluded 
from analysis because they did not complete the 
study. Each of these participants was exited from 
the study during the first week of participation, and 
the large majority (6/8) was exited from the study 
immediately because of a positive C. difficile anti-
gen test results, during phase 1 of the study. Two 
other participants were disenrolled when they were 
found to have clinical infections due to C. difficile. 
These infections, noted at day 3 and 8, were classi-
fied as existing before enrollment into the study by 
the principal investigator (WBG).
The table compares the lactoferrin group with the 
control group at enrollment. No significant dif-
ferences were found in comparisons between the 
two groups. However, shorter times since the last 
antibiotic therapy were observed in the lactofer-
rin group (p=0.07), and these participants were 
more likely to be enrolled in the second phase of 
the study (p=0.07).  
Fewer patients (4/9; 44.4%) in the lactoferrin group 
experienced diarrhoea compared to the control 
group (12/13; 92.3%; p=0.023). Those treated with 
lactoferrin were at a significantly reduced risk of ex-
periencing diarrhoea compared to the participants 
in the control group [odds ratio (OR)=0.07, 95% 
confidence interval (CI) 0.001-0.97]. Comparisons 
of the mean number of diarrhoea-days (control: 9.3 
vs lactoferrin: 4.0 days, p=0.072) and the percentage 
of the study days with diarrhoea (control: 17.1% 
vs lactoferrin: 8.0%, p=0.068) showed a trend to-
wards more diarrhoea in the control group. In addi-
tion, time-to-diarrhoea was shorter for the control 
group compared to the lactoferrin group (median 
time control: 7 vs lactoferrin: 60+ days, p=0.067). 
This trend can be seen in the figure, which shows 
the proportion of the participants free from diar-
rhoea as a function of time since enrollment into 
the study for lactoferrin (dashed line) and control 
(solid line) groups.   
During the study period, five participants (2 con-
trol and 3 lactoferrin) became infected with C. diffi-Prevention of post-antibiotic diarrhoea Laffan AM et al.
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Table. Characteristics of participants at enrollment
Characteristics
Lactoferrin (n=9) Control (n=13)
p value Mean
or no.
Range 
or % 
Mean or 
no.
Range 
or %
Age (years)  62.1 23.2-83.9 62.4 34.8-91.1 0.92
Male (no., %)  5  55.6 3  23.1 0.38
Black (no., %)  2  22.2 5  38.5 0.65
Anaemia (no.,%)* 5 55.6 4 30.8 0.24
Time (years) on unit  0.5 0.01-1.9 1.6 0.01-6.9 0.35
Time (years) on tube-feeding  0.85 0.14-5.17 0.64 0.04-2.54 0.57
Time (days) since last antibiotic  29 18-48 48 20-99  0.07
Phase 1 of study (no., %) 1  11.1 7  53.9 0.07
Time (days) in study  50.4 19-61 45.6 25-60 0.25
C. difficile antigen+ (no., %) 2  22.2 2  15.4 1.00
The differences between lactoferrin and control groups were tested using Fisher’s exact test for 
proportions and Wilcoxon signed-rank test for continuous parameters. *Anaemia was defined as 
use of ferrous sulphate
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Fig. Kaplan-Meier plot of time-to-diarrhoea
The vertical axis represents the proportion of the participants free of diarrhoea at a given time 
(horizontal axis) measured in days since enrollment into the study. Participants never experienc-
ing diarrhoea were censored at the last observed study date. The group receiving lactoferrin 
(dashed line) was compared with those given placebo (solid line)
cile (positive for C. difficile antigen and toxins), and 
of these participants, 2/2 in the control group and 
1/3 in the lactoferrin group experienced diarrhoea. 
The differences between control and lactoferrin 
groups were not significant (p>0.15 for both). 
DISCUSSION
Antibiotics destroy normal intestinal microbial flo-
ra often leading to diarrhoea (8). Older individuals 
in long-term care settings are particularly vulner-
able (9). The risk of morbidity or mortality due to 
diarrhoeal disease is higher in those aged over 65 
years (2). Although C. difficile is recognized as an 
important cause of AAD, evidence of infection due 
to C. difficile is found in less than half of all cases 
(3), and current treatment requires administration Laffan AM et al. Prevention of post-antibiotic diarrhoea
JHPN 550
of antibiotics. Alternative strategies are needed to 
prevent or treat C. difficile and other AADs. The pi-
lot study reported here tested human recombinant 
lactoferrin as a preventive tool against post-antibio-
tic diarrhoea. 
Lactoferrin, a normal human protein found in 
breastmilk and leukocytes, has both antibacterial 
and anti-inflammatory properties (5). This protein 
does not damage protective microbial flora of the 
intestine. Human lactoferrin was prepared by in-
serting the human gene into rice to prepare large 
amounts at low cost (10) and is nearly identical to 
native human lactoferrin (11). Administering high 
concentrations (5 mg/mL) of this product produced 
no adverse effects in our population of frail older 
adults, indicating that lactoferrin is safe.  
It was recently reported that recombinant lactofe-
rrin with lysozyme reduced the duration of diar-
rhoea compared to placebo controls in children 
when delivered via an oral rehydration solution 
(6). These results suggest that at least some of the 
effect of breastfeeding to prevent diarrhoea may be 
due to lactoferrin (12). Here, we have administered 
this breastmilk component to older individuals; 
with a result similar to the benefits to infants. Our 
results offer an interesting alternative approach to 
preventing and, perhaps, treating post-antibiotic 
diarrhoea. 
Although not the primary outcome, we did moni-
tor for C. difficile-associated infection. There were 
too few infections due to C. difficile to assess the ef-
fects of lactoferrin on this important cause of post-
antibiotic diarrhoea.
In this small study, we had observed a significant 
reduction in diarrhoea between treatment and pla-
cebo groups, suggesting that lactoferrin may be ef-
fective in preventing AAD. Caution should be taken 
in interpreting these results because this study was 
designed as a pilot project and enrolled a small 
number of patients. Further, we were forced to alter 
the study protocol mid-way through the project to 
achieve balance in treatment groups. However, giv-
en our significant findings, this novel preventive 
approach warrants further investigation in larger   
trials.  
In addition to efficacy trials, more research on the 
mechanisms through which lactoferrin may work 
to prevent AAD is needed. Results of research in-
dicate that human lactoferrin provides a readily-
absorbable source of iron to any patients with 
iron-deficiency anaemia (13), and this provides a 
possible additional benefit of lactoferrin adminis-
tration. We attempted to investigate this hypothe-
sis post-hoc using information on treatment for 
anaemia (use of ferrous sulphate) and red blood cell 
counts; however, due to the small sample-sizes and 
the post-hoc nature of the analysis, we were unable 
to show an effect of red blood cell counts in these 
patients. Future studies should consider the inclu-
sion of a full measure of iron status and parameters 
of anaemia to explicitly test the potential added 
benefit of administration of recombinant lactofer-
rin beyond its antibacterial and anti-inflammatory 
properties.
Lactoferrin when administered at the start of an-
tibiotic treatment reduced the attack rate of diar-
rhoea over an eight-week period. There were too   
few instances of C. difficile to assess the effects on 
this cause of post-antibiotic diarrhoea. Our results 
offer an interesting alternative approach to prevent-
ing and, perhaps, treating post-antibiotic diarrhoea. 
Further research should incorporate larger sample-
sizes powered to determine any effect on C. difficile 
as a serious complication of antibiotic therapy.    
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